Long a lobbying powerhouse in Washington, pharma’s struggling to settle on a strategy for defending itself, according to six industry lobbyists and three company officials who spoke to POLITICO. All ...

MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic ...

According to the latest report by FMI, the thionyl chloride industry size is projected to be worth USD 518.7 million in 2024 ...

The global health information exchange (HIE) market is projected to grow at a CAGR of 9-11% from 2024 to 2029. This growth is ...

Dasatinib Tablets US market size was approximately $1.8 billion for the 12 months ended February 2025, based on industry data ...

The pharmaceutical industry faces environmental challenges. Green chemistry offers sustainable solutions to reduce waste and ...

The Trump administration’s threat of pharmaceutical tariffs could risk significant political backlash, as the drug industry ...

The global herbal medicinal products market is projected to grow at a CAGR of 5-8% during the forecast period. Key drivers ...

An EO signed on April 15th is a solid first step toward improving drug affordability without diminishing the hope of patients ...

According to Benzinga Pro, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 5.87%, ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a $128 billion market cap. Renowned for its blockbuster drugs like Lipitor ...

Smith, Head of Business Development, Douglas CDMO, touts the advantages of and dispels misconceptions about mid-sized CDMOs.